Trial Profile
Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 12-weeks add-on treatment with LT-02 (gastro-resistant phosphatidylcholine granules) vs. placebo in patients with ulcerative colitis refractory to standard treatment with mesalamine
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Phosphatidylcholine (Primary) ; Mesalazine
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms PROTECT-1
- Sponsors Dr Falk Pharma
- 24 Oct 2018 Results presented at the 26th United European Gastroenterology Week
- 17 Nov 2017 This trial has been completed in Germany.
- 23 Sep 2017 This trial has been completed in Hungary